🇺🇸 FDA
Patent

US 11291709

Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies

granted A61KA61K38/26A61K38/28

Quick answer

US patent 11291709 (Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies) held by Rani Therapeutics, LLC expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rani Therapeutics, LLC
Grant date
Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/26, A61K38/28, A61K9/2018, A61K9/2027